SUNNYVALE, Calif., Feb. 1, 2012 /PRNewswire/ -- IntraOp Medical Corporation (OTC: IOPD) is pleased to announce that the German Supreme Court dismissed the patent nullification case that IntraOp Medical had appealed, and have upheld IntraOp's Mobetron patent for a mobile IOERT linear accelerator with "straight through" accelerator guide design without a bending magnet with a slight clarification.
IntraOp Medical's European Patent EP 0 700 578 describes for the Federal Republic of Germany an electron linear accelerator treatment device, which is suitable for Intra-Operative Electron Beam Radiation Therapy (IOERT). This patent has been maintained with a slight revision to better clarify the device. The German text of the European Patent EP 0 700 578 may be obtained from the German Patent and Trademark Office Link.
"It is good to have this ruling validate the inventiveness of the Mobetron, which has provided the clinical community a totally new way to deliver IOERT. The Mobetron mobile IOERT technology has already enabled important clinical studies in early stage breast cancer, and clinical trials for pancreatic cancer and rectal cancer are being developed. These studies would not have been practical or even possible to implement without the Mobetron mobile IOERT development," said Don Goer, Chief Scientist and founder of IntraOp. John Powers, IntraOp CEO further said "we will continue to aggressively defend our patents. This decision clearly helped reinforce the strength of our IP."
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications with excellent results. for example the IOERT Breast Boost has shown unparallel results in clinical studies for treating breast cancer with less than 1% recurrence in 10 years. The Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Contact: IntraOp Medical Corporation
John Powers, 408-636-1020 ext. 128 email: email@example.com
|SOURCE IntraOp Medical Corporation|
Copyright©2010 PR Newswire.
All rights reserved